LGND Q1 2021 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M+66.3% YoY

Gross Profit

$47M85.2% margin

Operating Income

$5M8.5% margin

Net Income

$18M32.8% margin

EPS (Diluted)

$1.05

QoQ Revenue Growth

-21.2%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$7M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$549M

Stockholders' Equity

$746M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$33M	+66.3%
Gross Profit	$47M	$28M	+65.0%
Operating Income	$5M	$4M	+24.5%
Net Income	$18M	-$24M	+175.0%

Revenue Segments

Material Sales, Captisol

$31M40%

Contract Revenue

$17M21%

Milestone

$8M11%

Royalty

$7M9%

Contract Revenue, Service

$5M7%

Kyprolis

$4M5%

Evomela

$2M3%

License Fees, Milestones, and Product, Other, Product, Other

$2M2%

License Fees

$1M1%

Royalty, Other

$492,0001%